US research roundup: Allstate, Caribou Biosciences, Zscaler
ALL•Analysts revised ratings and price targets for numerous U.S.-listed companies. HSBC raised Allstate to buy from hold, RBC cut Caribou Biosciences to sector perform from outperform and Jefferies raised Zscaler’s target to $250 from $220.
1. Selected analyst actions
HSBC raised its rating on Allstate to buy from hold and cut its target price to $266 from $282; Barclays cut its Allstate target to $221 from $226. RBC cut Caribou Biosciences to sector perform from outperform and lowered its target to $1 from $10.
2. Zscaler targets raised
Jefferies raised its Zscaler target price to $250 from $220. Other firms also raised targets: Barclays to $225 from $220, Canaccord Genuity to $250 from $210, Citigroup to $245 from $205, JPMorgan to $245 from $215 and Needham to $255 from $215.
3. Other notable revisions
The roundup also included multiple target increases for Marvell Technology, with Jefferies raising its target to $450 from $325, and a rating upgrade to buy from hold by TD Cowen. Analysts reported rating and target-price changes across many other companies.
